Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicat...
Kennedy Krieger Institute, Baltimore, Maryland, United States
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
McGill University, Montreal, Quebec, Canada
Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.